Adaptive Biotechnologies (ADPT) Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, community ranking, institutional ownership, profitability, dividends and analyst recommendations.

Does the MarketBeat Community favor ADPT or ADMA?

ADMA Biologics received 316 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 72.13% of users gave ADMA Biologics an outperform vote while only 57.99% of users gave Adaptive Biotechnologies an outperform vote.

Company	Underperform	Outperform
Adaptive Biotechnologies	Outperform Votes 98 57.99%	Underperform Votes 71 42.01%
ADMA Biologics	Outperform Votes 414 72.13%	Underperform Votes 160 27.87%

Do institutionals & insiders have more ownership in ADPT or ADMA?

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 6.2% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is ADPT or ADMA more profitable?

ADMA Biologics has a net margin of 17.80% compared to Adaptive Biotechnologies' net margin of -89.12%. ADMA Biologics' return on equity of 53.20% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-89.12%	-64.65%	-26.45%
ADMA Biologics	17.80%	53.20%	26.07%

Do analysts recommend ADPT or ADMA?

Adaptive Biotechnologies currently has a consensus target price of $9.40, suggesting a potential upside of 8.55%. ADMA Biologics has a consensus target price of $22.50, suggesting a potential upside of 10.73%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the media refer more to ADPT or ADMA?

In the previous week, ADMA Biologics had 5 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 17 mentions for ADMA Biologics and 12 mentions for Adaptive Biotechnologies. ADMA Biologics' average media sentiment score of 1.18 beat Adaptive Biotechnologies' score of 0.42 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, ADPT or ADMA?

Adaptive Biotechnologies has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Which has higher earnings and valuation, ADPT or ADMA?

ADMA Biologics has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$178.96M	7.19	-$159.49M	-$1.09	-7.94
ADMA Biologics	$426.45M	11.26	-$28.24M	$0.82	24.78

Summary

ADMA Biologics beats Adaptive Biotechnologies on 15 of the 19 factors compared between the two stocks.